TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24407163

Group type: EXPERIMENTAL
Intervention: Spanish-language Google AdWords campaign
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: English-language Google AdWords campaign
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Broad keywords (e.g., pregnancy)
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Spanish-speaking participants
Number of subjects: 2575
Study: 22945206

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both pharmacotherapy and psychotherapy
Number of subjects: 60
Study: 19255819

Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 25
Study: 16918891

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15298648

Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluvoxamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olanzapine alone
Number of subjects: 20
Study: 11783602

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (3 daily injections of regular insulin and 1 or 2 daily injections of intermediate acting insulin associated with metformin 500 mg twice daily in 64% of patients) in Group B (a) to achieve HbA1c < 7.5%.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg thrice daily) in Group B (b) to achieve HbA1c < 7.5%.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional metabolic therapy (sulphonylureas and/or biguanides) in Group A.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control of blood pressure using ACE inhibitors, beta blockers, calcium antagonists, and/or thiazides.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Not applicable (comparison of GFR decay between groups).
Number of subjects: 88
Study: 9408691

Group type: EXPERIMENTAL
Intervention: Urodilatin at a dose of 20 ng/kg/min for 7 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo infusion for 7 days
Number of subjects: 70
Study: 8381081

Group type: EXPERIMENTAL
Intervention: 3.6 mmol.kg body mass‐1 NaHCO3 (test, T)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 3.0 mmol.kg body mass‐1 CaCO3 (placebo, P)
Number of subjects: 6
Study: 3595071

Group type: EXPERIMENTAL
Intervention: Anirolac, 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Naproxen, 550 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anirolac, 50 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All active agents (Anirolac 50 mg, Anirolac 100 mg, Naproxen 550 mg)
Number of subjects: 120
Study: 31629852

Group type: EXPERIMENTAL
Intervention: CoQ10 (400 mg per day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 123
Study: 29635501

Group type: EXPERIMENTAL
Intervention: Weight-for-height or -length z score (WHZ) ≥ -2 at month 1
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Weight-for-height or -length z score (WHZ) ≥ -2 at month 3
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Weight-for-height or -length z score (WHZ) ≥ -2 at month 6
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Weight-for-height or -length z score (WHZ) < -3
Number of subjects: 1778
Study: 28067532

Group type: EXPERIMENTAL
Intervention: Mental stress-induced left ventricular ejection fraction change
Number of subjects: 310

Group type: COMPARATOR
Intervention: Exercise stress-induced myocardial ischemia (ESIMI)
Number of subjects: 310
Study: 26041872

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation catheter with integrated force sensor (TactiCath™) following EFFICAS I-based contact force (CF) guidelines (target 20 g, range 10-30 g, minimum 400 g s force-time integral).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation catheter with integrated force sensor (TactiCath™) following EFFICAS I-based contact force (CF) guidelines.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Not applicable (control group from EFFICAS I).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Not applicable (comparison of number of lesions).
Number of subjects: 24
Study: 23890931

Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide 25 mg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or calcium channel blocker
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Uncontrolled RH treatment
Number of subjects: 140
Study: 21940597

Group type: EXPERIMENTAL
Intervention: HAMSB40 (40 g cooked high‐amylose maize starch with 31.8 mmol esterified butyrate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HAMSB20 (20 g cooked high‐amylose maize starch with 31.8 mmol esterified butyrate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: HAMS (control group with high‐amylose maize starch)
Number of subjects: 16
Study: 18310366

Group type: EXPERIMENTAL
Intervention: Exteriorized uterine repair
Number of subjects: 637

Group type: COMPARATOR
Intervention: In situ uterine repair
Number of subjects: 637
Study: 15220698

Group type: EXPERIMENTAL
Intervention: saquinavir 1000 mg/ritonavir 100 mg every 12 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: amprenavir 600 mg/ritonavir 100 mg every 12 hours
Number of subjects: 11
Study: 11316688

Group type: EXPERIMENTAL
Intervention: Two antibiotics based on antibiotic susceptibility testing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Amoxycillin and clarithromycin for eight days, with either ranitidine or omeprazole
Number of subjects: 150
Study: 9934029

Group type: EXPERIMENTAL
Intervention: Dressing A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dressing B
Number of subjects: 0
Study: 7591850

Group type: EXPERIMENTAL
Intervention: Phenol alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined exposure to phenol, benzene, toluene, methyl ethyl ketone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 2500562

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 18
Study: 16326376

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 294
Study: 31769845

Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate Sodium (EC-MPS) plus low-dose prednisolone (0.25 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-dose prednisolone (1 mg/kg/day)
Number of subjects: 20
Study: 30878207

Group type: EXPERIMENTAL
Intervention: Low-threshold group (n = 44)
Number of subjects: 126

Group type: COMPARATOR
Intervention: High-threshold group (n = 44)
Number of subjects: 126
Study: 28531828

Group type: EXPERIMENTAL
Intervention: CT-based evaluation for DNT
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI-based evaluation for DNT
Number of subjects: 0
Study: 25451384

Group type: EXPERIMENTAL
Intervention: Applied tension
Number of subjects: 98

Group type: COMPARATOR
Intervention: No applied tension (Control)
Number of subjects: 98
Study: 23211356

Group type: EXPERIMENTAL
Intervention: Continued dual antiplatelet therapy (DAPT)
Number of subjects: 2157

Group type: COMPARATOR
Intervention: No continued dual antiplatelet therapy (DAPT)
Number of subjects: 2157
Study: 21511223

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: SYNTAX score (SXscore)
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: SYNTAX score (SXscore) tertiles
Number of subjects: 2033
Study: 19403844

Group type: EXPERIMENTAL
Intervention: Stage II or III tumor
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Poorly differentiated tumors
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Positive estrogen receptor status
Number of subjects: 3088
Study: 17005078

Group type: EXPERIMENTAL
Intervention: Plavix and Erigeron Injection (EI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Plavix alone (Control)
Number of subjects: 72
Study: 15612492

Group type: EXPERIMENTAL
Intervention: Yogurt (Y)
Number of subjects: 24
Study: 11085202

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study: 9303286

Group type: EXPERIMENTAL
Intervention: Subpubic penile block
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subcutaneous ring block
Number of subjects: 45
Study: 8367976

Group type: EXPERIMENTAL
Intervention: sustained‐release bezafibrate 400 mg daily (n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo (n = 19)
Number of subjects: 40
Study: 3788835

Group type: EXPERIMENTAL
Intervention: Oral-calcium supplementation (1500 mg Ca++/day for 6 wk)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 30103241

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 603

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 allele carriers in PGDE group
Number of subjects: 603
Study: 26860642

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Toe pressure measurements
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: ABI, ankle pressure, toe pressure
Number of subjects: 237
Study: 23945842

Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 57
Study: 22422777

Group type: COMPARATOR
Intervention: GnRH-antagonist (ganirelix or cetrorelix 0.25 mg starting on Day 6 of stimulation)
Number of subjects: 190

Group type: COMPARATOR
Intervention: GnRH-agonist (intranasal buserelin 600 mg per day starting on Day 21 of the preceding cycle)
Number of subjects: 190

Group type: COMPARATOR
Intervention: GnRH-agonist (progesterone >1.5 ng/ml)
Number of subjects: 190

Group type: COMPARATOR
Intervention: GnRH-antagonist (progesterone >1.5 ng/ml)
Number of subjects: 190
Study: 20307164

Group type: EXPERIMENTAL
Intervention: K10 'worst month in the past 12 months' version
Number of subjects: 12992

Group type: COMPARATOR
Intervention: K10 'past month' version
Number of subjects: 12992
Study: 18823565

Group type: EXPERIMENTAL
Intervention: Physical therapy interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16277137

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioural Therapy (CBT) alone
Number of subjects: 65

Group type: COMPARATOR
Intervention: SSRI antidepressant therapy (fluoxetine) alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combination of CBT plus fluoxetine
Number of subjects: 65
Study: 11926787

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 15
Study: 9469215

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) treatment for 7 weeks and continued for a mean of 55 weeks (range: 24-111 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo substitution after NT treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) treatment
Number of subjects: 50
Study: 7708855

Group type: EXPERIMENTAL
Intervention: Intensity modulated optical spectrometer at 807 nm
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intensity modulated optical spectrometer
Number of subjects: 135
Study: 2652027

Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5% solution for 3 days before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neosporin (combination antibiotic ophthalmic solution) for 3 days before surgery
Number of subjects: 40
Study: 1183355

Group type: EXPERIMENTAL
Intervention: 0.4 mg beta‐methyldigoxin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.4 mg digoxin
Number of subjects: 42
Study: 30658668

Group type: EXPERIMENTAL
Intervention: Augmented feedback during simulator training
Number of subjects: 40

Group type: COMPARATOR
Intervention: No augmented feedback (Control)
Number of subjects: 40
Study: 28661204

Group type: EXPERIMENTAL
Intervention: Compression brace (CB)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lace-up brace (LB)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Semirigid brace (SB)
Number of subjects: 86
Study: 26207902

Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 148
Study: 23453090

Group type: EXPERIMENTAL
Intervention: Intensive ambulatory blood pressure control (goal 24-hour systolic BP of ≤130 mm Hg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard ambulatory blood pressure control (goal 24-hour systolic BP of ≤145 mm Hg)
Number of subjects: 300
Study: 21946848

Group type: EXPERIMENTAL
Intervention: Strength training targeting the affected muscles (SST)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: General fitness training (GFT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: General health information (REF)
Number of subjects: 42
Study: 19169265

Group type: EXPERIMENTAL
Intervention: D-004 (320 mg) capsules administered daily for 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16507071

Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with acid etching and adhesive system (Excite DSC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with acid etching and adhesive system (Syntac)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with acid etching and adhesive system (Excite)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Flowable composite base (Tetric Flow Chroma) with adhesive system only (no acid etching)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group without adhesive system or acid etching
Number of subjects: 70
Study: 12752542

Group type: EXPERIMENTAL
Intervention: Preventive programs with varying fluoride content and contact with dental personnel
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Costs contributed by the patient and the patient's family
Number of subjects: 1165
Study: 17105328

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO(+)) - passive maxillary plates during the first year
Number of subjects: 41

Group type: COMPARATOR
Intervention: No infant orthopedics (IO(-))
Number of subjects: 41
Study: 10393475

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-16 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terazosin (1-2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8654637

Group type: EXPERIMENTAL
Intervention: Postcoital test (PCT)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Non-postcoital test (non-PCT)
Number of subjects: 290
Study: 1852180

Group type: EXPERIMENTAL
Intervention: Hypocaloric NCEP diet with exercise
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Hypocaloric NCEP diet
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264
Study: 6341944

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b (Hib) capsular polysaccharide vaccine
Number of subjects: 48997
Study: 27562219

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen 1 hour before surgery and another 600 mg 6 hours after the first dose
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone 1 hour before surgery and another 4 mg 6 hours after the first dose
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 26916172

Group type: EXPERIMENTAL
Intervention: 52-mg levonorgestrel (LNG-IUD)
Number of subjects: 3755

Group type: COMPARATOR
Intervention: Copper T 380 A IUD (TCu380A)
Number of subjects: 3755
Study: 24766686

Group type: EXPERIMENTAL
Intervention: Web-based technology for QOL data collection
Number of subjects: 49

Group type: COMPARATOR
Intervention: Paper forms for QOL data collection
Number of subjects: 49
Study: 22373033

Group type: EXPERIMENTAL
Intervention: Ziemer FEMTO LDV femtosecond laser
Number of subjects: 360

Group type: COMPARATOR
Intervention: Moria M2 mechanical microkeratome
Number of subjects: 360
Study: 20818286

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 829

Group type: COMPARATOR
Intervention: No prednisolone treatment (Control)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Overall population with early deterioration
Number of subjects: 829
Study: 17156903

Group type: EXPERIMENTAL
Intervention: Prior exposure and warning in upright standing posture
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stooped standing posture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Upright standing posture without prior experience or warning
Number of subjects: 30
Study: 15718316

Group type: EXPERIMENTAL
Intervention: Iridium implant (IM) plus external-beam radiation therapy (EBRT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: External-beam radiation therapy (EBRT) alone
Number of subjects: 104
Study: 12545683

Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Latanoprost (0.005%)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Timolol (0.5%)
Number of subjects: 132
Study: 9655717

Group type: EXPERIMENTAL
Intervention: 400 microg budesonide twice daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: 100 microg budesonide twice daily
Number of subjects: 84
Study: 7640129

Group type: EXPERIMENTAL
Intervention: Amethocaine gel 1 g (4% w/w)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo gel 1 g
Number of subjects: 42
Study: 2671191

Group type: EXPERIMENTAL
Intervention: Mechanical mitral valves
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Biological mitral valves
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Mechanical aortic valves
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Biological aortic valves
Number of subjects: 1281
Study: 30500926

Group type: EXPERIMENTAL
Intervention: Renal rehabilitation (RR) programme completion (attended >50% planned sessions)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Renal rehabilitation (RR) programme success (improvement in incremental shuttle walk test (ISWT) by ≥50 m)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Non-completers of RR
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Change in ISWT of >50 m
Number of subjects: 757
Study: 27717126

Group type: EXPERIMENTAL
Intervention: Exercise plus liraglutide
Number of subjects: 33

Group type: COMPARATOR
Intervention: Exercise plus placebo
Number of subjects: 33
Study: 25650733

Group type: EXPERIMENTAL
Intervention: Endurance training three times per week with 25-30% caloric restriction
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Strength training three times per week with 25-30% caloric restriction
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Combined endurance and strength training three times per week with 25-30% caloric restriction
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Following the American College of Sports Medicine physical activity guidelines for body weight loss with 25-30% caloric restriction
Number of subjects: 239
Study: 24930512

Group type: EXPERIMENTAL
Intervention: Nebulized methacholine inhalation (0.39 to 25 mg/ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (0.9%; control)
Number of subjects: 15
Study: 23071344

Group type: EXPERIMENTAL
Intervention: Massage intervention (weekly 45-minute massages for 4 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no massage intervention)
Number of subjects: 70
Study: 21288052

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg
Number of subjects: 14
Study: 17999217

Group type: EXPERIMENTAL
Intervention: Exercise condition
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control condition (disclosure of assigned experimental condition)
Number of subjects: 134
Study: 15652836

Group type: EXPERIMENTAL
Intervention: Nasal-hinged ACS microkeratome (NH) with 130 microm depth plate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal-hinged ACS microkeratome (NH) with 160 microm depth plate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Superior-hinged Hansatome microkeratome (SH) with 160 microm depth plate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Superior-hinged Hansatome microkeratome (SH) with 180 microm depth plate
Number of subjects: 40
Study: 11890185

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 10217889

Group type: EXPERIMENTAL
Intervention: Intervention group (mothers encouraged to engage in narrative conversation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study: 7734257

Group type: EXPERIMENTAL
Intervention: Morphine 20 mg administered before operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 10 mg at induction and 10 mg on closure of the peritoneum
Number of subjects: 0
Study: 2040933

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (100 units/kg twice each week for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 20
Study: 6120793

Group type: EXPERIMENTAL
Intervention: Propranolol administration
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 31844951

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: RF ablation
Number of subjects: 111
Study: 30938860

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D3
Number of subjects: 105

Group type: COMPARATOR
Intervention: Vitamin D3 alone
Number of subjects: 105